- Home
- INSM vs DVA Comparison
INSM vs DVA Comparison
Compare INSM & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- DVA
- Stock Information
- Founded
- INSM 1988
- DVA 1994
- Country
- INSM United States
- DVA United States
- Employees
- INSM N/A
- DVA N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- DVA Misc Health and Biotechnology Services
- Sector
- INSM Health Care
- DVA Health Care
- Exchange
- INSM Nasdaq
- DVA Nasdaq
- Market Cap
- INSM 14.3B
- DVA N/A
- IPO Year
- INSM 2000
- DVA 1995
- Fundamental
- Price
- INSM $76.29
- DVA $152.98
- Analyst Decision
- INSM Strong Buy
- DVA Hold
- Analyst Count
- INSM 16
- DVA 4
- Target Price
- INSM $95.36
- DVA $159.75
- AVG Volume (30 Days)
- INSM 1.5M
- DVA 884.6K
- Earning Date
- INSM 05-08-2025
- DVA 05-01-2025
- Dividend Yield
- INSM N/A
- DVA N/A
- EPS Growth
- INSM N/A
- DVA 44.61
- EPS
- INSM N/A
- DVA 10.73
- Revenue
- INSM $363,707,000.00
- DVA $12,815,550,000.00
- Revenue This Year
- INSM $30.31
- DVA $5.62
- Revenue Next Year
- INSM $118.39
- DVA $3.69
- P/E Ratio
- INSM N/A
- DVA $14.28
- Revenue Growth
- INSM 19.17
- DVA 5.56
- 52 Week Low
- INSM $21.92
- DVA $125.64
- 52 Week High
- INSM $84.91
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- INSM 46.23
- DVA 54.14
- Support Level
- INSM $76.05
- DVA $147.19
- Resistance Level
- INSM $79.12
- DVA $153.42
- Average True Range (ATR)
- INSM 2.52
- DVA 3.58
- MACD
- INSM -0.02
- DVA 1.27
- Stochastic Oscillator
- INSM 38.63
- DVA 93.01
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.